- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 28.07. | Roche expands phase 3 plans for Alzheimer's drug | ||
| 28.07. | Lilly's appeal unlocks EU approval of Alzheimer's drug | ||
| 28.07. | GSK forges $12bn alliance with China's Hengrui | ||
| 25.07. | UK MHRA green lights AbbVie's ELAHERE for ovarian cancer | ||
| 25.07. | Boehringer eyes H2 drug launches after strong H1 growth | ||
| 24.07. | GSK adds EU to Blenrep checklist as FDA sets new PDUFA date | ||
| 24.07. | AZ boasts phase 3 win for self-administered gMG drug | ||
| 24.07. | mRNA 'wake-up call' shows promise as universal cancer vaccine | ||
| 24.07. | EC clears first treatment for high-risk smouldering multiple myeloma | ||
| 24.07. | RFK Jr formally backs thimerosal ban in US vaccines | ||
| 23.07. | European Commission approves 2nd IPCEI to sum of €403m | ||
| 23.07. | AI health tech Respiree closes $11.6m Series A | ||
| 23.07. | Replimune receives CRL on BLA for RP1 for advanced melanoma | ||
| 22.07. | Scancell points to 'strong' melanoma vaccine data | ||
| 22.07. | AstraZeneca reveals $50bn investment in US facilities | ||
| 22.07. | Sarepta backs down and pauses Elevidys shipments | ||
| 22.07. | Sanofi to buy UK vaccines developer Vicebio for $1.6bn | ||
| 21.07. | FDA names a new CDER director, choosing a biotech vet | ||
| 21.07. | First-in-class hay fever immunotherapy backed for NHS use | ||
| 21.07. | Survival data back Tagrisso's role in first-line lung cancer | ||
| 21.07. | Merck's SpringWorks takeover delivers a drug approval | ||
| 21.07. | Roche's COPD candidate fails a phase 3 readout | ||
| 21.07. | Sarepta resists as FDA seeks pause on Elevidys use | ||
| 18.07. | Third death reported with a Sarepta gene therapy | ||
| 18.07. | BMS, Pfizer take DTC route for blood thinner Eliquis |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .